A Phase 1 interventional study of MK-7252 and Placebo in Pharmacokinetics and Cancer, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in Belgium. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-09.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of MK-7252 in healthy adults. Participants receive ascending doses of MK-7252 over five treatment periods. Each treatment period is separated by a 7-day washout period.
Upon review of the interim safety and preliminary PK data of human exposure to date, Protocol Amendment 3 includes a third panel of participants, Panel C, to assess the PK of higher doses of MK-7252 and to assess the food effect of MK-7252.
Three panels (Panels A, B, and C) of 8 healthy participants (n=6 MK-7252, n=2 placebo) are enrolled. In Panels A and B, participants will alternately receive single rising doses of MK-7252 or placebo for 5 treatment periods. In Panel C, participants will receive single rising doses of MK-7252 or placebo for up to 5 treatment periods. All doses in Panels A and B will be administered in the fasted state during the 5 treatment periods. Doses in Panel C will be administered in a fasted state in treatment periods 1 through 4 and the treatment period 1 dose will be repeated in a fed state during treatment period 5. Panel A will begin first. At least 3 days will elapse before participants in Panel B will receive the next higher dose. For all panels, there will be at least 7 days washout between treatment periods for any given participant. Participants may only be enrolled in one panel of the study. The planned dose levels may be adjusted downward or replaced based on evaluation of safety, tolerability, pharmacokinetic and/or pharmacodynamic data observed after previous treatment periods. All participants in the treatment periods of all panels (with exception of 120 mg fasted/fed periods in Panel C) will be randomly assigned to either study drug or placebo; that is a participant could be assigned to receive study drug in one period and placebo in another. As per the protocol allocation plan, the same participants in Panel C will receive 120 mg MK-7252 in a fasted and fed state. In addition, during any of the treatment periods if a participant demonstrates change in any one of the protocol-defined parameters lasting ≥2 hours, dose escalation in that participant will be halted and the participant may be withdrawn from the study or re-challenged at same dose or at a lower or divided dose. Participants that meet criteria listed will be followed up until parameters no longer meet stopping rule criteria.
During the study, participants in Panel A were planned to receive placebo, 1 mg, 6 mg, 24 mg, 72 mg and 108 mg, all in a fasted state in 5 periods. Participants in Panel B were planned to receive placebo, 3 mg, 12 mg, 48 mg, 72 mg and 162 mg, all in a fasted state in 5 periods. All periods in Panels A and B were conducted. Participants in Panel C were planned to receive placebo fasted, placebo fed, 120 mg fasted, 240 mg fasted, 360 mg fasted, 540 mg fasted, and 120 mg fed in 5 periods. Periods 4 and 5 were not conducted and, as a result, the 240 mg fasted, 360 mg fasted, 540 mg fasted, 120 mg fed, and placebo fed doses were not administered. A 180 mg fasted dose was added during Period 3.
10,834 studies on the registry are indexed under Neoplasms; 2,323 are open to participants now.
This study's enrollment of 24 is below the median of 60 across 7,714 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive either a single dose of MK-7252 or Placebo in a fasted state in each of five alternating treatment dosing periods as indicated. The planned dose levels include: Placebo for MK-7252, 1 mg of MK-7252, 6 mg of MK-7252, 24 mg of MK-7252, 72 mg of MK-7252, and 108 mg of MK-7252. There is a minimum of a 7-day washout period between each treatment period or dose administration. The planned dose levels may be adjusted downward or replaced based on evaluation of safety, tolerability, pharmacokinetic and/or pharmacodynamic data observed after previous treatment periods
Drug: MK-7252 · Drug: Placebo
Participants receive either a single dose of MK-7252 or Placebo in a fasted state in each of five alternating treatment dosing periods as indicated. The planned dose levels include: Placebo for MK-7252, 3 mg of MK-7252, 12 mg of MK-7252, 48 mg of MK-7252, 72 mg of MK-7252, and 162 mg of MK-7252. There is a minimum of a 7-day washout period between each treatment period or dose administration. The planned dose levels may be adjusted downward or replaced based on evaluation of safety, tolerability, pharmacokinetic and/or pharmacodynamic data observed after previous treatment periods
Drug: MK-7252 · Drug: Placebo
Participants receive either a single dose of MK-7252 or Placebo in up to 5 treatment dosing periods as indicated: Placebo for MK-7252, 120 mg of MK-7252 in a fasted state, 240 mg of MK-7252, 360 mg of MK-7252, 540 mg of MK-7252, and 120 mg of MK-7252 in a fed state. There is a minimum of a 7-day washout period between each treatment period or dose administration. The planned dose levels may be adjusted downward or replaced based on evaluation of safety, tolerability, pharmacokinetic and/or pharmacodynamic data observed after previous treatment periods
Drug: MK-7252 · Drug: Placebo
1 mg/mL or 20 mg/mL of powder for oral suspension administered with a water volume that brings the total ingested volume to approximately 240 mL
Placebo powder for oral suspension administered with a water volume that brings the total ingested volume to approximately 240 mL
Number of Participants Who Experienced at Least One Adverse Event (AE)
An AE was defined as any untoward medical occurrence in a participant administered study treatment and which did not necessarily have to have had a causal relationship with this treatment. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of study treatment, was also an AE. Adverse events are reported by dose taken at time of event and not by panel or period. The adverse events for placebo are pooled over periods across panels. The number of participants who experienced at least one AE is presented.
Time frame: Up to approximately 21 weeks
Number of Participants Who Discontinued Study Treatment Due to an AE
An AE was defined as any untoward medical occurrence in a participant administered study treatment and which did not necessarily have to have had a causal relationship with this treatment. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of study treatment, was also an AE. Discontinuations are reported by dose taken at time of event. The discontinuations for placebo are pooled over periods across panels. The number of participants who discontinued study treatment due to an AE is presented.
Time frame: Up to approximately 19 weeks
MK-7252 Area Under the Concentration-Time Curve From Zero to Infinity (AUC0-∞)
Blood samples were obtained predose (Day 1) and at designated times postdose to calculate the plasma MK-7252 AUC0-∞ reported as back-transformed least squares mean and confidence interval calculated using a linear mixed effects model performed on natural log-transformed values. Pharmacokinetic (PK) results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma AUC0-∞ following a high-fat breakfast (fed state) was planned to be compared to the plasma AUC0-∞ in the fasted stated in Panel C, the fed state dose was not administered.
Time frame: Predose (Day 1) and 0.25, 0.5, 1, 2, 4, 8, 10, 12, 24, 48, and 72 hours postdose
MK-7252 Area Under the Concentration-Time Curve From Zero to 24 Hours Postdose (AUC0-24hr)
Blood samples were obtained predose (Day 1) and at designated times postdose to calculate the plasma MK-7252 AUC0-24hr reported as back-transformed least squares mean and confidence interval calculated using a linear mixed effects model performed on natural log-transformed values. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma AUC0-24hr following a high-fat breakfast (fed state) was planned to be compared to the plasma AUC0-24hr in the fasted stated in Panel C, the fed state dose was not administered.
Time frame: Predose (Day 1), 0.25, 0.5, 1, 2, 4, 8, 10, 12, and 24 hours postdose
MK-7252 Area Under the Concentration-Time Curve From Zero to 12 Hours Postdose (AUC0-12hr)
Blood samples were obtained predose (Day 1) and at designated times postdose to calculate the plasma MK-7252 AUC0-12hr reported as back-transformed least squares mean and confidence interval calculated using a linear mixed effects model performed on natural log-transformed values. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma AUC0-12hr following a high-fat breakfast (fed state) was planned to be compared to the plasma AUC0-12hr in the fasted stated in Panel C, the fed state dose was not administered.
Time frame: Predose (Day 1), 0.25, 0.5, 1, 2, 4, 8, 10, and 12 hours postdose
MK-7252 Area Under the Concentration-Time Curve From Zero to Last Measurable Concentration (AUClast)
Blood samples were obtained predose (Day 1) and at designated times postdose to calculate the plasma MK-7252 AUClast reported as back-transformed least squares mean and confidence interval calculated using a linear mixed effects model performed on natural log-transformed values. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma AUClast following a high-fat breakfast (fed state) was planned to be compared to the plasma AUClast in the fasted stated in Panel C, the fed state dose was not administered.
Time frame: Predose (Day 1), 0.25, 0.5, 1, 2, 4, 8, 10, 12, 24, 48, and 72 hours postdose
MK-7252 Maximal Plasma Concentration (Cmax)
Blood samples were obtained predose (Day 1) and at designated times postdose to calculate the plasma MK-7252 Cmax reported as back-transformed least squares mean and confidence interval calculated using a linear mixed effects model performed on natural log-transformed values. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma Cmax following a high-fat breakfast (fed state) was planned to be compared to the plasma Cmax in the fasted stated in Panel C, the fed state dose was not administered.
Time frame: Predose (Day 1), 0.25, 0.5, 1, 2, 4, 8, 10, 12, 24, 48, and 72 hours postdose
MK-7252 Plasma Concentration at 12 Hours Postdose (C12hr)
Blood samples were obtained 12 hours postdose to calculate the plasma MK-7252 C12hr reported as back-transformed least squares mean and confidence interval calculated using a linear mixed effects model performed on natural log-transformed values. For participants in a given dose that had C12hr values less than the lower limit of quantification (LLOQ), the C12hr value was imputed as half x LLOQ. The LLOQ was 2.74 nmol/L. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma C12hr following a high-fat breakfast (fed state) was planned to be compared to the plasma C12hr in the fasted stated in Panel C, the fed state dose was not administered.
Time frame: 12 hours postdose
MK-7252 Plasma Concentration at 24 Hours Postdose (C24hr)
Blood samples were obtained 24 hours postdose to calculate the plasma MK-7252 C24hr reported as back-transformed least squares mean and confidence interval calculated using a linear mixed effects model performed on natural log-transformed values. For participants in a given dose that had C24hr values less than the lower limit of quantification (LLOQ), the C24hr value was imputed as half x LLOQ. The LLOQ was 2.74 nmol/L. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma C24hr following a high-fat breakfast (fed state) was planned to be compared to the plasma C24hr in the fasted stated in Panel C, the fed state dose was not administered.
Time frame: 24 hours postdose
MK-7252 Time to Reach Maximal Concentration (Tmax)
Blood samples were obtained predose (Day 1) and at designated times postdose to calculate the plasma MK-7252 Tmax. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma Tmax following a high-fat breakfast (fed state) was planned to be compared to the plasma Tmax in the fasted stated in Panel C, the fed state dose was not administered.
Time frame: Predose (Day 1), 0.25, 0.5, 1, 2, 4, 8, 10, 12, 24, 48, and 72 hours postdose
MK-7252 Apparent Terminal Half-life (t½)
Blood samples were obtained predose (Day 1) and at designated times postdose to calculate the plasma MK-7252 t½ reported as Geometric Mean with Percent Geometric Coefficient of Variation. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma t½ following a high-fat breakfast (fed state) was planned to be compared to the plasma t½ in the fasted stated in Panel C, the fed state dose was not administered.
Time frame: Predose (Day 1), 0.25, 0.5, 1, 2, 4, 8, 10, 12, 24, 48, and 72 hours postdose
Change From Baseline in Systolic Blood Pressure (SBP) at 4 Hours
Assessment of the change from baseline in SBP was obtained using a validated, semi-automated oscillometric device. Baseline was defined as the average of predose measurements. A measurement set was considered 2 SBP measurements: baseline and 4 hours postdose. SBP results are reported by dose taken. Placebo measurements are pooled over periods across panels. A positive number indicates an increase in SBP and a negative number indicates a decrease in SBP.
Time frame: Baseline (Predose Day 1) and 4 hours postdose
Change From Baseline in Systolic Blood Pressure (SBP) at 24 Hours
Assessment of the change from baseline in SBP was obtained using a validated, semi-automated oscillometric device. Baseline was defined as the average of predose measurements. A measurement set was considered 2 SBP measurements: baseline and 24 hours postdose. SBP results are reported by dose taken. Placebo measurements are pooled over periods across panels. A positive number indicates an increase in SBP and a negative number indicates a decrease in SBP.
Time frame: Baseline (Predose Day 1) and 24 hours postdose
Change From Baseline in Diastolic Blood Pressure (DBP) at 4 Hours
Assessment of the change from baseline in DBP was obtained using a validated, semi-automated oscillometric device. Baseline was defined as the average of predose measurements. A measurement set was considered 2 DBP measurements: baseline and 4 hours postdose. DBP results are reported by dose taken. Placebo measurements are pooled over periods across panels. A positive number indicates an increase in DBP and a negative number indicates a decrease in DBP.
Time frame: Baseline (Predose Day 1) and 4 hours postdose
Change From Baseline in Diastolic Blood Pressure (DBP) at 24 Hours
Assessment of the change from baseline in DBP was obtained using a validated, semi-automated oscillometric device. Baseline was defined as the average of predose measurements. A measurement set was considered 2 DBP measurements: baseline and 24 hours postdose. DBP results are reported by dose taken. Placebo measurements are pooled over periods across panels. A positive number indicates an increase in DBP and a negative number indicates a decrease in DBP.
Time frame: Baseline (Predose Day 1) and 24 hours postdose
Change From Baseline in Heart Rate (HR) at 4 Hours
Assessment of the change from baseline in HR was obtained using a validated, semi-automated oscillometric device. Baseline was defined as the average of predose measurements. A measurement set was considered 2 HR measurements: baseline and 4 hours postdose. HR results are reported by dose taken. Placebo measurements are pooled over periods across panels. A positive number indicates an increase in HR and a negative number indicates a decrease in HR.
Time frame: Baseline (Predose Day 1) and 4 hours postdose
Change From Baseline in Heart Rate (HR) at 24 Hours
Assessment of the change from baseline in HR was obtained using a validated, semi-automated oscillometric device. Baseline was defined as the average of predose measurements. A measurement set was considered 2 HR measurements: baseline and 24 hours postdose. HR results are reported by dose taken. Placebo measurements are pooled over periods across panels. A positive number indicates an increase in HR and a negative number indicates a decrease in HR.
Time frame: Baseline (Predose Day 1) and 24 hours postdose
| Milestone | Panel A | Panel B | Panel C |
|---|---|---|---|
| Started | 8 | 8 | 8 |
| Completed | 8 | 8 | 8 |
| Not completed | 0 | 0 | 0 |
An AE was defined as any untoward medical occurrence in a participant administered study treatment and which did not necessarily have to have had a causal relationship with this treatment. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of study treatment, was also an AE. Adverse events are reported by dose taken at time of event and not by panel or period. The adverse events for placebo are pooled over periods across panels. The number of participants who experienced at least one AE is presented.
| Participants | MK-7252 1 mg | MK-7252 3 mg | MK-7252 6 mg | MK-7252 12 mg | MK-7252 24 mg | MK-7252 48 mg | MK-7252 72 mg | MK-7252 108 mg | MK-7252 120 mg | MK-7252 162 mg | MK-7252 180 mg | Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Who Experienced at Least One Adverse Event (AE) | 2 | 5 | 4 | 5 | 5 | 4 | 7 | 5 | 6 | 4 | 2 | 15 |
An AE was defined as any untoward medical occurrence in a participant administered study treatment and which did not necessarily have to have had a causal relationship with this treatment. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of study treatment, was also an AE. Discontinuations are reported by dose taken at time of event. The discontinuations for placebo are pooled over periods across panels. The number of participants who discontinued study treatment due to an AE is presented.
| Participants | MK-7252 1 mg | MK-7252 3 mg | MK-7252 6 mg | MK-7252 12 mg | MK-7252 24 mg | MK-7252 48 mg | MK-7252 72 mg | MK-7252 108 mg | MK-7252 120 mg | MK-7252 162 mg | MK-7252 180 mg | Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Who Discontinued Study Treatment Due to an AE | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
Blood samples were obtained predose (Day 1) and at designated times postdose to calculate the plasma MK-7252 AUC0-∞ reported as back-transformed least squares mean and confidence interval calculated using a linear mixed effects model performed on natural log-transformed values. Pharmacokinetic (PK) results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma AUC0-∞ following a high-fat breakfast (fed state) was planned to be compared to the plasma AUC0-∞ in the fasted stated in Panel C, the fed state dose was not administered.
| hr•nmol/L | Panel A MK-7252 1 mg | Panel B MK-7252 3 mg | Panel A MK-7252 6 mg | Panel B MK-7252 12 mg | Panel A MK-7252 24 mg | Panel B MK-7252 48 mg | Panel A MK-7252 72 mg | Panel B MK-7252 72 mg | Panel A MK-7252 108 mg | Panel B MK-7252 162 mg | Panel C MK-7252 120 mg Period 1 | Panel C MK-7252 120 mg Period 2 | Panel C MK-7252 180 mg Period 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MK-7252 Area Under the Concentration-Time Curve From Zero to Infinity (AUC0-∞) | NA (NA to NA) | NA (NA to NA) | 288 (195 to 427) | 583 (394 to 862) | 1190 (805 to 1750) | 2040 (1390 to 3000) | 5090 (3460 to 7490) | 3500 (2380 to 5160) | 6680 (4530 to 9840) | 9840 (6690 to 14500) | 7260 (4930 to 10700) | 5520 (3720 to 8170) | 10300 (6970 to 15300) |
Blood samples were obtained predose (Day 1) and at designated times postdose to calculate the plasma MK-7252 AUC0-24hr reported as back-transformed least squares mean and confidence interval calculated using a linear mixed effects model performed on natural log-transformed values. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma AUC0-24hr following a high-fat breakfast (fed state) was planned to be compared to the plasma AUC0-24hr in the fasted stated in Panel C, the fed state dose was not administered.
| hr•nmol/L | Panel A MK-7252 1 mg | Panel B MK-7252 3 mg | Panel A MK-7252 6 mg | Panel B MK-7252 12 mg | Panel A MK-7252 24 mg | Panel B MK-7252 48 mg | Panel A MK-7252 72 mg | Panel B MK-7252 72 mg | Panel A MK-7252 108 mg | Panel B MK-7252 162 mg | Panel C MK-7252 120 mg Period 1 | Panel C MK-7252 120 mg Period 2 | Panel C MK-7252 180 mg Period 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MK-7252 Area Under the Concentration-Time Curve From Zero to 24 Hours Postdose (AUC0-24hr) | 47.8 (32.4 to 70.4) | 122 (82.4 to 179) | 279 (189 to 411) | 559 (379 to 824) | 1150 (781 to 1700) | 2030 (1380 to 3000) | 5210 (3530 to 7680) | 3490 (2370 to 5150) | 6420 (4350 to 9470) | 9530 (6460 to 14100) | 7240 (4900 to 10700) | 5510 (3710 to 8200) | 10300 (6910 to 15300) |
Blood samples were obtained predose (Day 1) and at designated times postdose to calculate the plasma MK-7252 AUC0-12hr reported as back-transformed least squares mean and confidence interval calculated using a linear mixed effects model performed on natural log-transformed values. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma AUC0-12hr following a high-fat breakfast (fed state) was planned to be compared to the plasma AUC0-12hr in the fasted stated in Panel C, the fed state dose was not administered.
| hr•nmol/L | Panel A MK-7252 1 mg | Panel B MK-7252 3 mg | Panel A MK-7252 6 mg | Panel B MK-7252 12 mg | Panel A MK-7252 24 mg | Panel B MK-7252 48 mg | Panel A MK-7252 72 mg | Panel B MK-7252 72 mg | Panel A MK-7252 108 mg | Panel B MK-7252 162 mg | Panel C MK-7252 120 mg Period 1 | Panel C MK-7252 120 mg Period 2 | Panel C MK-7252 180 mg Period 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MK-7252 Area Under the Concentration-Time Curve From Zero to 12 Hours Postdose (AUC0-12hr) | 47.8 (32.5 to 70.4) | 121 (82.5 to 179) | 278 (189 to 409) | 558 (379 to 822) | 1140 (775 to 1680) | 2020 (1370 to 2980) | 5130 (3480 to 7540) | 3450 (2340 to 5070) | 6220 (4220 to 9160) | 9240 (6270 to 13600) | 7170 (4860 to 10600) | 5480 (3690 to 8130) | 10200 (6840 to 15100) |
Blood samples were obtained predose (Day 1) and at designated times postdose to calculate the plasma MK-7252 AUClast reported as back-transformed least squares mean and confidence interval calculated using a linear mixed effects model performed on natural log-transformed values. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma AUClast following a high-fat breakfast (fed state) was planned to be compared to the plasma AUClast in the fasted stated in Panel C, the fed state dose was not administered.
| hr•nmol/L | Panel A MK-7252 1 mg | Panel B MK-7252 3 mg | Panel A MK-7252 6 mg | Panel B MK-7252 12 mg | Panel A MK-7252 24 mg | Panel B MK-7252 48 mg | Panel A MK-7252 72 mg | Panel B MK-7252 72 mg | Panel A MK-7252 108 mg | Panel B MK-7252 162 mg | Panel C MK-7252 120 mg Period 1 | Panel C MK-7252 120 mg Period 2 | Panel C MK-7252 180 mg Period 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MK-7252 Area Under the Concentration-Time Curve From Zero to Last Measurable Concentration (AUClast) | 38.7 (26.0 to 57.6) | 101 (68.1 to 151) | 250 (168 to 371) | 543 (365 to 808) | 1130 (757 to 1680) | 2030 (1360 to 3020) | 5170 (3470 to 7690) | 3420 (2300 to 5090) | 6330 (4250 to 9420) | 9750 (6550 to 14500) | 7250 (4860 to 10800) | 5500 (3670 to 8260) | 10300 (6860 to 15500) |
Blood samples were obtained predose (Day 1) and at designated times postdose to calculate the plasma MK-7252 Cmax reported as back-transformed least squares mean and confidence interval calculated using a linear mixed effects model performed on natural log-transformed values. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma Cmax following a high-fat breakfast (fed state) was planned to be compared to the plasma Cmax in the fasted stated in Panel C, the fed state dose was not administered.
| nmol/L | Panel A MK-7252 1 mg | Panel B MK-7252 3 mg | Panel A MK-7252 6 mg | Panel B MK-7252 12 mg | Panel A MK-7252 24 mg | Panel B MK-7252 48 mg | Panel A MK-7252 72 mg | Panel B MK-7252 72 mg | Panel A MK-7252 108 mg | Panel B MK-7252 162 mg | Panel C MK-7252 120 mg Period 1 | Panel C MK-7252 120 mg Period 2 | Panel C MK-7252 180 mg Period 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MK-7252 Maximal Plasma Concentration (Cmax) | 21.2 (15.4 to 29.4) | 51.7 (37.4 to 71.5) | 117 (84.6 to 162) | 220 (159 to 305) | 447 (323 to 618) | 830 (600 to 1150) | 1860 (1340 to 2570) | 1380 (997 to 1910) | 2290 (1660 to 3170) | 3380 (2440 to 4670) | 3160 (2280 to 4380) | 2550 (1820 to 3580) | 3880 (2760 to 5440) |
Blood samples were obtained 12 hours postdose to calculate the plasma MK-7252 C12hr reported as back-transformed least squares mean and confidence interval calculated using a linear mixed effects model performed on natural log-transformed values. For participants in a given dose that had C12hr values less than the lower limit of quantification (LLOQ), the C12hr value was imputed as half x LLOQ. The LLOQ was 2.74 nmol/L. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma C12hr following a high-fat breakfast (fed state) was planned to be compared to the plasma C12hr in the fasted stated in Panel C, the fed state dose was not administered.
| nmol/L | Panel A MK-7252 1 mg | Panel B MK-7252 3 mg | Panel A MK-7252 6 mg | Panel B MK-7252 12 mg | Panel A MK-7252 24 mg | Panel B MK-7252 48 mg | Panel A MK-7252 72 mg | Panel B MK-7252 72 mg | Panel A MK-7252 108 mg | Panel B MK-7252 162 mg | Panel C MK-7252 120 mg Period 1 | Panel C MK-7252 120 mg Period 2 | Panel C MK-7252 180 mg Period 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MK-7252 Plasma Concentration at 12 Hours Postdose (C12hr) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | 2.19 (1.17 to 4.10) | 2.95 (1.57 to 5.51) | 11.7 (6.29 to 21.7) | 7.06 (3.80 to 13.1) | 21.0 (11.2 to 39.2) | 31.8 (17.0 to 59.6) | 10.4 (5.59 to 19.3) | 7.16 (3.76 to 13.7) | 16.7 (8.77 to 31.9) |
Blood samples were obtained 24 hours postdose to calculate the plasma MK-7252 C24hr reported as back-transformed least squares mean and confidence interval calculated using a linear mixed effects model performed on natural log-transformed values. For participants in a given dose that had C24hr values less than the lower limit of quantification (LLOQ), the C24hr value was imputed as half x LLOQ. The LLOQ was 2.74 nmol/L. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma C24hr following a high-fat breakfast (fed state) was planned to be compared to the plasma C24hr in the fasted stated in Panel C, the fed state dose was not administered.
| nmol/L | Panel A MK-7252 1 mg | Panel B MK-7252 3 mg | Panel A MK-7252 6 mg | Panel B MK-7252 12 mg | Panel A MK-7252 24 mg | Panel B MK-7252 48 mg | Panel A MK-7252 72 mg | Panel B MK-7252 72 mg | Panel A MK-7252 108 mg | Panel B MK-7252 162 mg | Panel C MK-7252 120 mg Period 1 | Panel C MK-7252 120 mg Period 2 | Panel C MK-7252 180 mg Period 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MK-7252 Plasma Concentration at 24 Hours Postdose (C24hr) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Blood samples were obtained predose (Day 1) and at designated times postdose to calculate the plasma MK-7252 Tmax. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma Tmax following a high-fat breakfast (fed state) was planned to be compared to the plasma Tmax in the fasted stated in Panel C, the fed state dose was not administered.
| hr | Panel A MK-7252 1 mg | Panel B MK-7252 3 mg | Panel A MK-7252 6 mg | Panel B MK-7252 12 mg | Panel A MK-7252 24 mg | Panel B MK-7252 48 mg | Panel A MK-7252 72 mg | Panel B MK-7252 72 mg | Panel A MK-7252 108 mg | Panel B MK-7252 162 mg | Panel C MK-7252 120 mg Period 1 | Panel C MK-7252 120 mg Period 2 | Panel C MK-7252 180 mg Period 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MK-7252 Time to Reach Maximal Concentration (Tmax) | 1.00 (0.50 to 1.00) | 0.75 (0.50 to 1.00) | 0.75 (0.50 to 1.00) | 1.00 (0.50 to 1.00) | 1.00 (0.50 to 1.00) | 0.75 (0.50 to 1.00) | 1.00 (0.50 to 2.00) | 1.00 (0.50 to 1.00) | 0.75 (0.50 to 1.00) | 0.75 (0.50 to 1.00) | 0.75 (0.50 to 1.00) | 1.00 (0.50 to 1.00) | 1.00 (0.50 to 1.00) |
Blood samples were obtained predose (Day 1) and at designated times postdose to calculate the plasma MK-7252 t½ reported as Geometric Mean with Percent Geometric Coefficient of Variation. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma t½ following a high-fat breakfast (fed state) was planned to be compared to the plasma t½ in the fasted stated in Panel C, the fed state dose was not administered.
| hr | Panel A MK-7252 1 mg | Panel B MK-7252 3 mg | Panel A MK-7252 6 mg | Panel B MK-7252 12 mg | Panel A MK-7252 24 mg | Panel B MK-7252 48 mg | Panel A MK-7252 72 mg | Panel B MK-7252 72 mg | Panel A MK-7252 108 mg | Panel B MK-7252 162 mg | Panel C MK-7252 120 mg Period 1 | Panel C MK-7252 120 mg Period 2 | Panel C MK-7252 180 mg Period 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MK-7252 Apparent Terminal Half-life (t½) | NA ± NA | NA ± NA | 1.29 ± 12.18 | 1.34 ± 14.99 | 1.60 ± 19.86 | 1.35 ± 9.93 | 1.76 ± 60.34 | 1.59 ± 19.54 | 3.09 ± 81.14 | 5.97 ± 92.18 | 1.96 ± 52.80 | 2.40 ± 71.03 | 2.90 ± 152.97 |
Assessment of the change from baseline in SBP was obtained using a validated, semi-automated oscillometric device. Baseline was defined as the average of predose measurements. A measurement set was considered 2 SBP measurements: baseline and 4 hours postdose. SBP results are reported by dose taken. Placebo measurements are pooled over periods across panels. A positive number indicates an increase in SBP and a negative number indicates a decrease in SBP.
| mmHg | Panel A MK-7252 1 mg | Panel B MK-7252 3 mg | Panel A MK-7252 6 mg | Panel B MK-7252 12 mg | Panel A MK-7252 24 mg | Panel B MK-7252 48 mg | Panel A MK-7252 72 mg | Panel B MK-7252 72 mg | Panel A MK-7252 108 mg | Panel B MK-7252 162 mg | Panel C MK-7252 120 mg Period 1 | Panel C MK-7252 120 mg Period 2 | Panel C MK-7252 180 mg Period 3 | Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Systolic Blood Pressure (SBP) at 4 Hours | 5.61 ± 1.94 | 1.56 ± 2.57 | 0.50 ± 2.66 | 4.39 ± 2.08 | 6.78 ± 3.71 | 12.17 ± 1.57 | 14.00 ± 4.28 | 9.83 ± 0.84 | 11.28 ± 1.90 | 5.33 ± 2.15 | 18.17 ± 7.65 | 3.80 ± 4.15 | 6.13 ± 4.52 | 3.22 ± 1.84 |
Assessment of the change from baseline in SBP was obtained using a validated, semi-automated oscillometric device. Baseline was defined as the average of predose measurements. A measurement set was considered 2 SBP measurements: baseline and 24 hours postdose. SBP results are reported by dose taken. Placebo measurements are pooled over periods across panels. A positive number indicates an increase in SBP and a negative number indicates a decrease in SBP.
| mmHg | Panel A MK-7252 1 mg | Panel B MK-7252 3 mg | Panel A MK-7252 6 mg | Panel B MK-7252 12 mg | Panel A MK-7252 24 mg | Panel B MK-7252 48 mg | Panel A MK-7252 72 mg | Panel B MK-7252 72 mg | Panel A MK-7252 108 mg | Panel B MK-7252 162 mg | Panel C MK-7252 120 mg Period 1 | Panel C MK-7252 120 mg Period 2 | Panel C MK-7252 180 mg Period 3 | Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Systolic Blood Pressure (SBP) at 24 Hours | 2.83 ± 3.40 | 0.89 ± 3.00 | -1.11 ± 1.56 | -3.56 ± 2.47 | -0.17 ± 2.75 | -0.56 ± 2.48 | 7.56 ± 1.32 | 3.56 ± 1.81 | 0.22 ± 3.36 | 3.17 ± 1.61 | 4.67 ± 3.51 | -0.13 ± 4.98 | 7.27 ± 3.86 | 5.84 ± 1.48 |
Assessment of the change from baseline in DBP was obtained using a validated, semi-automated oscillometric device. Baseline was defined as the average of predose measurements. A measurement set was considered 2 DBP measurements: baseline and 4 hours postdose. DBP results are reported by dose taken. Placebo measurements are pooled over periods across panels. A positive number indicates an increase in DBP and a negative number indicates a decrease in DBP.
| mmHg | Panel A MK-7252 1 mg | Panel B MK-7252 3 mg | Panel A MK-7252 6 mg | Panel B MK-7252 12 mg | Panel A MK-7252 24 mg | Panel B MK-7252 48 mg | Panel A MK-7252 72 mg | Panel B MK-7252 72 mg | Panel A MK-7252 108 mg | Panel B MK-7252 162 mg | Panel C MK-7252 120 mg Period 1 | Panel C MK-7252 120 mg Period 2 | Panel C MK-7252 180 mg Period 3 | Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Diastolic Blood Pressure (DBP) at 4 Hours | 1.11 ± 1.77 | 1.61 ± 1.06 | 0.33 ± 1.88 | 2.28 ± 3.24 | 6.33 ± 1.55 | 6.22 ± 1.56 | 5.50 ± 2.03 | 7.28 ± 2.24 | 4.61 ± 1.24 | 5.33 ± 1.43 | 5.28 ± 1.24 | 11.27 ± 3.12 | 5.67 ± 1.96 | 0.61 ± 0.83 |
Assessment of the change from baseline in DBP was obtained using a validated, semi-automated oscillometric device. Baseline was defined as the average of predose measurements. A measurement set was considered 2 DBP measurements: baseline and 24 hours postdose. DBP results are reported by dose taken. Placebo measurements are pooled over periods across panels. A positive number indicates an increase in DBP and a negative number indicates a decrease in DBP.
| mmHg | Panel A MK-7252 1 mg | Panel B MK-7252 3 mg | Panel A MK-7252 6 mg | Panel B MK-7252 12 mg | Panel A MK-7252 24 mg | Panel B MK-7252 48 mg | Panel A MK-7252 72 mg | Panel B MK-7252 72 mg | Panel A MK-7252 108 mg | Panel B MK-7252 162 mg | Panel C MK-7252 120 mg Period 1 | Panel C MK-7252 120 mg Period 2 | Panel C MK-7252 180 mg Period 3 | Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Diastolic Blood Pressure (DBP) at 24 Hours | 0.61 ± 1.31 | 2.78 ± 3.13 | -2.67 ± 2.86 | -3.33 ± 2.23 | 2.33 ± 1.69 | -1.11 ± 2.03 | 2.11 ± 1.91 | 1.72 ± 1.62 | -0.78 ± 2.49 | 4.11 ± 1.89 | 1.28 ± 1.59 | 4.00 ± 1.15 | 4.73 ± 1.16 | 1.99 ± 0.83 |
Assessment of the change from baseline in HR was obtained using a validated, semi-automated oscillometric device. Baseline was defined as the average of predose measurements. A measurement set was considered 2 HR measurements: baseline and 4 hours postdose. HR results are reported by dose taken. Placebo measurements are pooled over periods across panels. A positive number indicates an increase in HR and a negative number indicates a decrease in HR.
| beats per minute | Panel A MK-7252 1 mg | Panel B MK-7252 3 mg | Panel A MK-7252 6 mg | Panel B MK-7252 12 mg | Panel A MK-7252 24 mg | Panel B MK-7252 48 mg | Panel A MK-7252 72 mg | Panel B MK-7252 72 mg | Panel A MK-7252 108 mg | Panel B MK-7252 162 mg | Panel C MK-7252 120 mg Period 1 | Panel C MK-7252 120 mg Period 2 | Panel C MK-7252 180 mg Period 3 | Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Heart Rate (HR) at 4 Hours | -4.22 ± 1.82 | -0.28 ± 2.66 | -1.22 ± 1.68 | -0.89 ± 1.76 | 0.22 ± 0.88 | 0.17 ± 1.72 | 6.83 ± 7.05 | 2.28 ± 2.99 | 0.83 ± 2.21 | 1.33 ± 2.10 | 2.17 ± 6.07 | -1.53 ± 1.36 | 1.27 ± 2.15 | -1.27 ± 0.91 |
Assessment of the change from baseline in HR was obtained using a validated, semi-automated oscillometric device. Baseline was defined as the average of predose measurements. A measurement set was considered 2 HR measurements: baseline and 24 hours postdose. HR results are reported by dose taken. Placebo measurements are pooled over periods across panels. A positive number indicates an increase in HR and a negative number indicates a decrease in HR.
| beats per minute | Panel A MK-7252 1 mg | Panel B MK-7252 3 mg | Panel A MK-7252 6 mg | Panel B MK-7252 12 mg | Panel A MK-7252 24 mg | Panel B MK-7252 48 mg | Panel A MK-7252 72 mg | Panel B MK-7252 72 mg | Panel A MK-7252 108 mg | Panel B MK-7252 162 mg | Panel C MK-7252 120 mg Period 1 | Panel C MK-7252 120 mg Period 2 | Panel C MK-7252 180 mg Period 3 | Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Heart Rate (HR) at 24 Hours | -2.78 ± 2.01 | 2.72 ± 2.03 | 1.83 ± 1.38 | 3.89 ± 1.55 | 2.89 ± 1.19 | 1.67 ± 1.41 | 2.94 ± 1.73 | 2.17 ± 2.15 | -0.61 ± 1.46 | 2.67 ± 2.18 | -0.72 ± 2.53 | 1.40 ± 1.26 | 2.33 ± 1.13 | 2.23 ± 1.27 |
Collected over Up to approximately 21 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MK-7252 1 mg | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| MK-7252 3 mg | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| MK-7252 6 mg | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| MK-7252 12 mg | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| MK-7252 24 mg | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| MK-7252 48 mg | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| MK-7252 72 mg | 0/12 (0%) | 0/12 (0%) | 7/12 (58.3%) |
| MK-7252 108 mg | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| MK-7252 120 mg | 0/8 (0%) | 0/8 (0%) | 6/8 (75%) |
| MK-7252 162 mg | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| MK-7252 180 mg | 0/5 (0%) | 0/5 (0%) | 2/5 (40%) |
| Placebo | 0/22 (0%) | 0/22 (0%) | 15/22 (68.2%) |
| Post-Study | 0/24 (0%) | 0/24 (0%) | 3/24 (12.5%) |
| Event | MK-7252 1 mg | MK-7252 3 mg | MK-7252 6 mg | MK-7252 12 mg | MK-7252 24 mg | MK-7252 48 mg | MK-7252 72 mg | MK-7252 108 mg | MK-7252 120 mg | MK-7252 162 mg | MK-7252 180 mg | Placebo | Post-Study |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 1/6 | 3/6 | 2/6 | 1/6 | 2/6 | 0/6 | 1/12 | 2/6 | 1/8 | 2/6 | 0/5 | 8/22 | 1/24 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 3/6 | 0/8 | 0/6 | 0/5 | 2/22 | 0/24 |
| NauseaGastrointestinal disorders | 0/6 | 1/6 | 0/6 | 2/6 | 1/6 | 0/6 | 0/12 | 0/6 | 0/8 | 0/6 | 0/5 | 2/22 | 0/24 |
| Feeling of body temperature changeGeneral disorders | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 2/6 | 1/12 | 0/6 | 0/8 | 0/6 | 0/5 | 0/22 | 0/24 |
| DizzinessNervous system disorders | 0/6 | 0/6 | 0/6 | 2/6 | 0/6 | 1/6 | 0/12 | 0/6 | 0/8 | 0/6 | 0/5 | 2/22 | 0/24 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 0/6 | 0/6 | 2/6 | 1/6 | 1/6 | 0/6 | 1/12 | 0/6 | 0/8 | 0/6 | 0/5 | 0/22 | 0/24 |
| FlatulenceGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/6 | 2/8 | 0/6 | 1/5 | 0/22 | 0/24 |
| Abdominal discomfortGastrointestinal disorders | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/6 | 0/8 | 0/6 | 1/5 | 0/22 | 0/24 |
| Abdominal painGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/12 | 0/6 | 0/8 | 0/6 | 1/5 | 1/22 | 0/24 |
| PalpitationsCardiac disorders | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 2/12 | 0/6 | 1/8 | 0/6 | 0/5 | 0/22 | 0/24 |
All randomized participants
| Age, Continuous(Years) | Panel A | Panel B | Panel C | Total |
|---|---|---|---|---|
| Mean | 33.0 ± 10.2 | 35.0 ± 9.5 | 34.4 ± 9.3 | 34.1 ± 9.3 |
| Sex: Female, Male(Participants) | Panel A | Panel B | Panel C | Total |
|---|---|---|---|---|
| Female | 1 | 2 | 0 | 3 |
| Male | 7 | 6 | 8 | 21 |
| Ethnicity (NIH/OMB)(Participants) | Panel A | Panel B | Panel C | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 8 | 8 | 8 | 24 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Panel A | Panel B | Panel C | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 8 | 8 | 8 | 24 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Nov 2017 to primary completion in Dec 2018, 13 months.
Results were first posted in Jan 2020, 1 year after primary completion.
Of 676 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's 13 months is below that.
Counting every sponsor, half of 903 studies reached it within 40 months; a quarter within 23 and three quarters within 64.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.